- Trials with a EudraCT protocol (273)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
273 result(s) found for: Ovariectomy.
Displaying page 1 of 14.
| EudraCT Number: 2006-001652-12 | Sponsor Protocol Number: ICA 17043-12 | Start Date*: Information not available in EudraCT |
| Sponsor Name:Icagen Inc. | ||
| Full Title: An Open-Label Extension Study Evaluating the Long-Term Safety of ICA 17043 with or without Hydroxyurea Therapy in Subjects with Sickle Cell Disease | ||
| Medical condition: Sickle Cell Disease | ||
| Disease: | ||
| Population Age: Adolescents, Under 18, Adults | Gender: Male, Female | |
| Trial protocol: FR (Ongoing) GB (Completed) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2007-006082-32 | Sponsor Protocol Number: 2293/2007 | Start Date*: 2007-12-13 | |||||||||||
| Sponsor Name:AZIENDA OSPEDALIERA PISANA | |||||||||||||
| Full Title: Female steroid hormones and protection from cardiovascular risk: staminal endothelial progenitor cells and menopause. | |||||||||||||
| Medical condition: Postmenopause | |||||||||||||
|
|||||||||||||
| Population Age: Adults | Gender: Female | ||||||||||||
| Trial protocol: IT (Completed) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2017-000458-20 | Sponsor Protocol Number: 108160 | Start Date*: 2017-11-14 |
| Sponsor Name:GlaxoSmithKline Biologicals | ||
| Full Title: A post-marketing surveillance (PMS) study to monitor the safety and reactogenicity of GlaxoSmithKline (GSK) Biologicals’ human papillo-mavirus (HPV) vaccine (Cervarix) in 3,000 healthy female Filip... | ||
| Medical condition: Healthy volunteers (active immunization against Human papillomavirus infection in female subjects for the prevention of cervical cancer). | ||
| Disease: | ||
| Population Age: Children, Adolescents, Under 18, Adults | Gender: Female | |
| Trial protocol: Outside EU/EEA | ||
| Trial results: View results | ||
| EudraCT Number: 2016-004322-42 | Sponsor Protocol Number: CICL670A2402E1 | Start Date*: 2017-08-31 |
| Sponsor Name:Novartis Pharma Services AG | ||
| Full Title: Efficacy and safety of long-term treatment with ICL670 in beta-thalassemia patients with transfusional hemosiderosis | ||
| Medical condition: Tranfusional hemosiderosis | ||
| Disease: | ||
| Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | |
| Trial protocol: Outside EU/EEA | ||
| Trial results: View results | ||
| EudraCT Number: 2007-005203-18 | Sponsor Protocol Number: 110551 | Start Date*: 2008-06-24 |
| Sponsor Name:GlaxoSmithKline Biologicals | ||
| Full Title: An open Phase II study of immunization with the recMAGE-A3 + AS01B Antigen-Specific Cancer Immunotherapeutic in patients with MAGE-A3-positive unresectable and progressive metastatic cutaneous mela... | ||
| Medical condition: MAGE-A3-positive unresectable and progressive metastatic cutaneous melanoma. | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: GR (Prematurely Ended) | ||
| Trial results: View results | ||
| EudraCT Number: 2009-010088-17 | Sponsor Protocol Number: MID/09 | Start Date*: 2009-02-16 | |||||||||||
| Sponsor Name:AZIENDA OSPEDALIERA OSPEDALI GALLIERA | |||||||||||||
| Full Title: Whole liver iron overload measured by the biosusceptometer Magnetic Iron Detector (MID) in thalassemia and MDS patients treated with deferasirox | |||||||||||||
| Medical condition: Patients with diagnosis of thalassemia major with iron overload or regularly transfused MDS patients (Low/Intermediate-1 IPSS risk and 1 year life expectancy) | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: IT (Ongoing) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2007-000261-38 | Sponsor Protocol Number: 108988 | Start Date*: 2008-01-21 |
| Sponsor Name:GlaxoSmithKline Biologicals | ||
| Full Title: A phase IV, open, multicentric study to evaluate the immune response to a hepatitis B challenge dose in healthy subjects, 72 to 78 months after they received a primary vaccination course of GSK Bio... | ||
| Medical condition: Hepatitis B vaccine challenge dose given to subjects, 17 to 21 years of age, to evaluate immune memory to Hepatitis B antigen, approximately 6 years after priming with Hepatitis B vaccine. | ||
| Disease: | ||
| Population Age: Adolescents, Under 18, Adults | Gender: Male, Female | |
| Trial protocol: BE (Completed) | ||
| Trial results: View results | ||
| EudraCT Number: 2011-001429-25 | Sponsor Protocol Number: 2011.0704 | Start Date*: 2011-08-23 |
| Sponsor Name:University Medical Center Groningen | ||
| Full Title: Feasibility Study: FES-PET to determine ER-expression in epithelial ovarian cancer | ||
| Medical condition: epithelial ovarian cancer | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Female | |
| Trial protocol: NL (Ongoing) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2006-004201-26 | Sponsor Protocol Number: NC200602 | Start Date*: 2007-03-15 |
| Sponsor Name:Neuro-Consil GmbH | ||
| Full Title: Efficacy and tolerability of flexible dose adjusted pregabalin as first-line add-on treatment of patients with focal seizures | ||
| Medical condition: epilepsis with seizures of focal origin | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: DE (Prematurely Ended) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2007-007055-13 | Sponsor Protocol Number: CTU 043C | Start Date*: 2009-07-17 |
| Sponsor Name:RIEMSER Arzneimittel AG | ||
| Full Title: DOUBLE-BLIND, RANDOMISED, PLACEBO-CONTROLLED PROSPECTIVE MULTI-CENTRE PHASE III TRIAL TO ASSESS THE EFFICACY AND SAFETY OF METHANTHELINIUM BROMIDE (VAGANTIN®) IN THE TREATMENT OF FOCAL PALMAR-AXILL... | ||
| Medical condition: Treatment of patients with axillary and palmar hyperhidrosis | ||
| Disease: | ||
| Population Age: Adults | Gender: Male, Female | |
| Trial protocol: DE (Completed) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2010-019994-13 | Sponsor Protocol Number: RD.03.SPR.40117E | Start Date*: 2010-09-21 | |||||||||||
| Sponsor Name:GALDERMA R&D | |||||||||||||
| Full Title: EXPLORATORY STUDY TO EVALUATE THE SAFETY AND EFFICACY OF CD07387 SOLUTION IN PATIENTS WITH VITILIGO | |||||||||||||
| Medical condition: Vitiligo | |||||||||||||
|
|||||||||||||
| Population Age: Adults | Gender: Male, Female | ||||||||||||
| Trial protocol: FR (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2020-003877-23 | Sponsor Protocol Number: IMPROVE-MC | Start Date*: 2022-03-22 | |||||||||||
| Sponsor Name:Medical University of Warsaw | |||||||||||||
| Full Title: A multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy of immunosuppression in biopsy-proven virus negative myocarditis or inflammatory cardiomyopathy (IMPROVE-... | |||||||||||||
| Medical condition: Myocarditis, inflammatory cardiomyopathy | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: PL (Trial now transitioned) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2006-003073-27 | Sponsor Protocol Number: RD.03.SPR29064 | Start Date*: 2007-02-06 | |||||||||||
| Sponsor Name:Galderma R&D | |||||||||||||
| Full Title: Subject preference comparison between Clobetasol propionate shampoo, 0.05% and three other topical corticosteroids in the treatment of moderate to severe Scalp psoriasis | |||||||||||||
| Medical condition: Moderate to Severe Scalp Psoriasis with a Global Severity Score of 3 at least on a scale from 0 to 5. | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: GB (Completed) IT (Completed) DE (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2009-012188-32 | Sponsor Protocol Number: 113094 | Start Date*: 2009-09-17 |
| Sponsor Name:GlaxosmithKline Biologicals | ||
| Full Title: A phase III, observer-blind, multicountry, multicentre study to evaluate the safety, reactogenicity and immunogenicity of GlaxoSmithKline Biologicals’ GSK2186877A influenza vaccine administered to ... | ||
| Medical condition: Immunization against influenza in male and female subjects aged 19-43 years and 66 years or older. | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: NL (Completed) SE (Completed) DE (Completed) | ||
| Trial results: View results | ||
| EudraCT Number: 2015-002168-17 | Sponsor Protocol Number: BAY94-8862/16275 | Start Date*: 2015-12-09 | |||||||||||||||||||||||||||||||
| Sponsor Name:Bayer HealthCare AG | |||||||||||||||||||||||||||||||||
| Full Title: A multicenter, randomized, double-blind, double-dummy, parallel-group, active-controlled study to evaluate the efficacy and safety of finerenone compared to eplerenone on morbidity and mortality in... | |||||||||||||||||||||||||||||||||
| Medical condition: Subjects with chronic heart failure and reduced ejection fraction after recent heart failure decompensation and additional risk factors, either type 2 diabetes mellitus or chronic kidney disease or... | |||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||||||||||||
| Trial protocol: SE (Prematurely Ended) DK (Prematurely Ended) IE (Prematurely Ended) CZ (Prematurely Ended) DE (Prematurely Ended) FI (Prematurely Ended) GB (Prematurely Ended) AT (Prematurely Ended) HU (Prematurely Ended) NL (Prematurely Ended) PT (Prematurely Ended) ES (Prematurely Ended) LT (Prematurely Ended) BG (Prematurely Ended) PL (Prematurely Ended) GR (Prematurely Ended) IT (Prematurely Ended) | |||||||||||||||||||||||||||||||||
| Trial results: View results | |||||||||||||||||||||||||||||||||
| EudraCT Number: 2007-002880-29 | Sponsor Protocol Number: 110263 | Start Date*: 2007-09-13 |
| Sponsor Name:GlaxoSmithKline Biologicals | ||
| Full Title: A phase II, open, controlled study to evaluate the reactogenicity and the immunogenicity of GlaxoSmithKline Biologicals AS25 adjuvanted influenza vaccine (FluAS25) in elderly adults (≥66 years) pre... | ||
| Medical condition: Immunization against influenza in male and female subjects aged 66 years and older. | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: BE (Completed) | ||
| Trial results: View results | ||
| EudraCT Number: 2009-011212-37 | Sponsor Protocol Number: RD.03.SPR.29084 | Start Date*: 2010-01-06 | |||||||||||
| Sponsor Name:Galderma research & Development | |||||||||||||
| Full Title: Anti P. acnes activity of Epiduo® Gel compared to Benzoyl Peroxide 2.5% Gel in the treatment of subjects with acne vulgaris | |||||||||||||
| Medical condition: Acne vulgaris with a high level of P. Acnes on the face (obeserved under wood's lamp) | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: PL (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2009-015997-36 | Sponsor Protocol Number: 113809 | Start Date*: 2009-10-08 |
| Sponsor Name:GlaxoSmithKline Biologicals | ||
| Full Title: A phase III, double-blind, randomized, study in adults aged between 18 and 60 years to assess the immunological non-inferiority of two manufacturing processes of the A/California/7/2009 (H1N1)v-lik... | ||
| Medical condition: Immunization against A/California/7/2009 (H1N1)v-like influenza in male and female subjects aged 18 to 60 years. | ||
| Disease: | ||
| Population Age: Adults | Gender: Male, Female | |
| Trial protocol: DE (Completed) | ||
| Trial results: View results | ||
| EudraCT Number: 2009-010811-34 | Sponsor Protocol Number: 113018 | Start Date*: 2009-04-16 |
| Sponsor Name:GlaxoSmithKline Biologicals | ||
| Full Title: A Phase III, open, non-randomized, multi-centric, single dose study to assess mmunogenicity and safety of Fluarix / Influsplit SSW® 2009/2010 injected intramuscularly in young adults (18 to 60 year... | ||
| Medical condition: Immunization against influenza of healthy adults. | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: DE (Completed) | ||
| Trial results: View results | ||
| EudraCT Number: 2004-003803-19 | Sponsor Protocol Number: WXL101497 | Start Date*: 2004-11-10 |
| Sponsor Name:GlaxoSmithKline Research & Development | ||
| Full Title: A Multi-Centre, Randomised, Double-Blind, Parallel-Group, Placebo- and Active- Controlled, Flexible Dose Study Evaluating the Efficacy, Safety and Tolerability of Extended-Release Bupropion Hydroch... | ||
| Medical condition: Major Depressive Disorder (MDD) | ||
| Disease: | ||
| Population Age: Adults | Gender: Male, Female | |
| Trial protocol: SE (Completed) | ||
| Trial results: View results | ||
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
| Download Options: | |
|---|---|
| Number of Trials to download: | |
| Download Content: | |
| Download Format: | |
| Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. | |
Query did not match any studies.